Impact of perioperative low-molecular-weight heparin therapy on clinical events of elderly patients with prior coronary stents implanted > 12 months undergoing non-cardiac surgery: a randomized, placebo-controlled trial
BMC Medicine · 2024
DOI: 10.1186/s12916-024-03391-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BMC Medicine, 2024. Verfasst von Bin Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comprehensive Surgery, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospit…. Hauptthemen laut MEDLINE: Stents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCIRD CDC HHS, National Center for Immunization and Respiratory Diseases, National Key R&D Program of China.
Abstract (Originalsprache)
Background
Little is known about the safety and efficacy of discontinuing antiplatelet therapy via LMWH bridging therapy in elderly patients with coronary stents implanted for > 12 months undergoing non-cardiac surgery. This randomized trial was designed to compare the clinical benefits and risks of antiplatelet drug discontinuation via LMWH bridging therapy.
Methods
Patients were randomized 1:1 to receive subcutaneous injections of either dalteparin sodium or placebo. The primary efficacy endpoint was cardiac or cerebrovascular events. The primary safety endpoint was major bleeding.
Results
Among 2476 randomized patients, the variables (sex, age, body mass index, comorbidities, medications, and procedural characteristics) and percutaneous coronary intervention information were not significantly different between the bridging and non-bridging groups. During the follow-up period, the rate of the combined endpoint in the bridging group was significantly lower than in the non-bridging group (5.79% vs. 8.42%, p = 0.012). The incidence of myocardial injury in the bridging group was significantly lower than in the non-bridging group (3.14% vs. 5.19%, p = 0.011). Deep vein thrombosis occurred more frequently in the non-bridging group (1.21% vs. 0.4%, p = 0.024), and there was a trend toward a higher rate of pulmonary embolism (0.32% vs. 0.08%, p = 0.177). There was no significant difference between the groups in the rates of acute myocardial infarction (0.81% vs. 1.38%), cardiac death (0.24% vs. 0.41%), stroke (0.16% vs. 0.24%), or major bleeding (1.22% vs. 1.45%). Multivariable analysis showed that LMWH bridging, creatinine clearance < 30 mL/min, preoperative hemoglobin < 10 g/dL, and diabetes mellitus were independent predictors of ischemic events. LMWH bridging and a preoperative platelet count of < 70 × 10 9 /L were independent predictors of minor bleeding events.
Conclusions
This study showed the safety and efficacy of perioperative LMWH bridging therapy in elderly patients with coronary stents implanted > 12 months undergoing non-cardiac surgery. An alternative approach might be the use of bridging therapy with half-dose LMWH.
Trial registration
ISRCTN65203415.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comprehensive Surgery, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China.
- Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
- National Research Institute for Family Planning, Beijing, China.
- Department of Thoracic Surgery of The First Medical Center, General Hospital of Chinese People's Liberation Army, Beijing, 100853, China. chenleighcpl@163.com.
- Department of Comprehensive Surgery, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China. litianzhi301@sina.com.
- Department of Comprehensive Surgery, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China. gaolinggen@163.com.
Förderung
- NCIRD CDC HHS
- National Center for Immunization and Respiratory Diseases
- National Key R&D Program of China
Zitieren
APA
Wang, B., Su, Y., Ma, C., Xu, L., Mao, Q., Cheng, W., Lu, Q., Zhang, Y., Wang, R., Lu, Y., He, J., Chen, S., Chen, L., Li, T., & Gao, L. (2024). Impact of perioperative low-molecular-weight heparin therapy on clinical events of elderly patients with prior coronary stents implanted > 12 months undergoing non-cardiac surgery: a randomized, placebo-controlled trial. BMC Medicine. https://doi.org/10.1186/s12916-024-03391-2
Vancouver
Wang B, Su Y, Ma C, Xu L, Mao Q, Cheng W, et al. Impact of perioperative low-molecular-weight heparin therapy on clinical events of elderly patients with prior coronary stents implanted > 12 months undergoing non-cardiac surgery: a randomized, placebo-controlled trial. BMC Medicine. 2024. doi:10.1186/s12916-024-03391-2
BibTeX
@article{Wang2024,
author = {Wang, Bin and Su, Yanhui and Ma, Cong and Xu, Lining and Mao, Qunxia and Cheng, Wenjia and Lu, Qingming and Zhang, Ying and Wang, Rong and Lu, Yan and He, Jing and Chen, Shihao and Chen, Lei and Li, Tianzhi and Gao, Linggen},
title = {Impact of perioperative low-molecular-weight heparin therapy on clinical events of elderly patients with prior coronary stents implanted > 12 months undergoing non-cardiac surgery: a randomized, placebo-controlled trial},
journal = {BMC Medicine},
year = {2024},
doi = {10.1186/s12916-024-03391-2}
}
EUVIMED